These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 25773310)

  • 1. T cell metabolic fitness in antitumor immunity.
    Siska PJ; Rathmell JC
    Trends Immunol; 2015 Apr; 36(4):257-64. PubMed ID: 25773310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of the fittest: Cancer challenges T cell metabolism.
    Franchina DG; He F; Brenner D
    Cancer Lett; 2018 Jan; 412():216-223. PubMed ID: 29074426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting T cell metabolism for immunotherapy.
    Gao J; Liu Y; Wei J; Jiang L; Mao J; Chang CH; Wu D
    J Leukoc Biol; 2021 Dec; 110(6):1081-1090. PubMed ID: 34779530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunometabolism: A new target for improving cancer immunotherapy.
    Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
    Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunctional T cell metabolism in the tumor microenvironment.
    Beckermann KE; Dudzinski SO; Rathmell JC
    Cytokine Growth Factor Rev; 2017 Jun; 35():7-14. PubMed ID: 28456467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
    Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
    J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between Immune Checkpoint Proteins and Cellular Metabolism.
    Lim S; Phillips JB; Madeira da Silva L; Zhou M; Fodstad O; Owen LB; Tan M
    Cancer Res; 2017 Mar; 77(6):1245-1249. PubMed ID: 28246276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy.
    Yang R; Hung MC
    Sci China Life Sci; 2017 Oct; 60(10):1058-1064. PubMed ID: 29027155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncology meets immunology: the cancer-immunity cycle.
    Chen DS; Mellman I
    Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging concepts of T cell metabolism as a target of immunotherapy.
    Chang CH; Pearce EL
    Nat Immunol; 2016 Apr; 17(4):364-8. PubMed ID: 27002844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Barriers to T Cell Function in Tumors.
    Sugiura A; Rathmell JC
    J Immunol; 2018 Jan; 200(2):400-407. PubMed ID: 29311381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic Competition in Tumor Microenvironment].
    Eikawa S; Udono H
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):972-976. PubMed ID: 29138369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
    Li X; Xu W
    Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
    Ho PC; Kaech SM
    Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Complex Integration of T-cell Metabolism and Immunotherapy.
    Madden MZ; Rathmell JC
    Cancer Discov; 2021 Jul; 11(7):1636-1643. PubMed ID: 33795235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.